| 半导体 | | | | | --- | --- | --- | --- | | 5993.473 ↓ -190.805 -3.09% | | | 公易中 | | : 图目 . | | | | | 最高价 6251.265 | 开盘价 6173.043 | 成交量 2270.27万 | | | 最低价 5981.270 | 昨收价 6184.278 | 成交额 13.99亿 | | | 市盈率 212.695 | 换手率 0.11% | 总市值 1.01万亿 (m) | | | 市净率 4.182 | 平均价 6116.268 | 流通值 7174.9亿 | | | 上 涨4 | 平 盘 3 | 下 跌 10 | | | 52周最高 6251.265历史最高 6251.265 | | | | | 52周最低 1607.153历史最低 665.310 | 14 | | | 消息面上，高盛上调中芯国际和华虹半导体港股目标价，称中国不断扩大的AI生态为半导体带来机 遇。将两家公司的目标价均上调至117港元，此前中芯国际和华虹半导体目标价分别为95港元和87港 元。分析师Allen Chang等人在报告中表示："随 ...

Core Viewpoint - The company, InnoCare Pharma (02577.HK), has submitted an application to the China Securities Regulatory Commission to convert 373,841,270 domestic unlisted shares into H-shares, aiming for full circulation of H-shares [1] Summary by Relevant Sections Company Actions - InnoCare Pharma has applied for the conversion of 373,841,270 domestic unlisted shares into H-shares, which will allow these shares to be traded on the Hong Kong Stock Exchange after obtaining necessary regulatory approvals [1] - The total share capital of the company is 894,400,653 shares, with H-shares totaling 504,841,187 shares, representing approximately 56.44% of the total share capital [1] Shareholder Communication - Communication with all holders of domestic unlisted shares indicates that 373,841,270 shares, or about 95.97% of the total domestic unlisted shares, support the H-share full circulation application, which accounts for approximately 41.80% of the company's total share capital [1] Post-Conversion Structure - Upon completion of the H-share full circulation, the total number of H-shares will increase to 878,682,457 shares, representing approximately 98.24% of the company's total share capital, while the number of domestic unlisted shares will decrease to 15,718,196 shares, accounting for about 1.76% of the total share capital [1]

Core Viewpoint - InnoCare Pharma (02577) has submitted an application to the China Securities Regulatory Commission (CSRC) to convert 374 million domestic unlisted shares into H-shares, aiming for listing on the Hong Kong Stock Exchange [1] Group 1 - The company submitted the application on September 29, 2025 [1] - The conversion of domestic unlisted shares into H-shares is contingent upon obtaining approvals from relevant regulatory bodies, including the CSRC and the Hong Kong Stock Exchange [1] - Upon completion of the necessary regulatory approvals and compliance with applicable laws and regulations, the shares will be eligible for trading on the main board of the Hong Kong Stock Exchange [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 InnoScience (Suzhou) Technology Holding Co., Ltd. 英 諾 賽 科（ 蘇 州 ）科 技 股 份 有 限 公 司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2577） 內幕消息 本公司申請H股全流通 本公告由英諾賽科（蘇州）科技股份有限公司（「本公司」）根據香港聯合交易所有限 公司（「聯交所」）證券上市規則（「上市規則」）第13.09(2)(a)條及香港法例第571章 證券及期貨條例第XIVA部項下的內幕消息條文（定義見上市規則）作出。 茲提述中國證券監督管理委員會（「中國證監會」）於2019年11月14日發佈並於 2023年8月10日進一步修訂的《H股公司境內未上市股份申請「全流通」業務指引》 及中國證監會於2023年2月17日發佈的《境內企業境外發行證券和上市管理試行辦 法》，內容有關聯交所上市H股公司申請股份全流通程序的指引。 本公司董事 ...

董事會成員及僱員多元化政策 InnoScience (Suzhou) Technology Holding Co., Ltd. 英 諾 賽 科（ 蘇 州 ）科 技 股 份 有 限 公 司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2577） 第一章 總則 第一條 根據《中華人民共和國公司法》《香港聯合交易所有限公司證券上市 規則》等相關法律、法規、規範性文件、公司股票上市地證券監管規則以及《英諾 賽科（蘇州）科技股份有限公司章程》（以下簡稱「《公司章程》」）的有關規定，本政 策的目的旨在列出指引英諾賽科（蘇州）科技股份有限公司（以下簡稱「公司」）董 事會（以下簡稱「董事會」）提名董事及為達到董事會成員及全體僱員（包括高級管 理人員）多元化而採取的方針和政策。 第二條 多元化是本集團的核心價值之一，公司尊重每一位員工的個體多樣 性，包括但不限於種族、膚色、性別、宗教、國籍、性取向或其他受法律保護的 身份等方面。員工多元化應遵循合法合規原則、平等包容原則和同工同酬原則。 第二章 一般要求 第三條 所有董事會成員及全體僱員（包括高級管理人員）之任命均以用人唯 才為原則，並在考慮人選時以適當的條件充分顧 ...

InnoScience (Suzhou) Technology Holding Co., Ltd. 英 諾 賽 科（ 蘇 州 ）科 技 股 份 有 限 公 司 （於中華人民共和國註冊成立的股份有限公司） （「本公司」） （股份代號：2577） 提名委員會職權範圍 1. 成員 2. 秘書 3. 會議通知 3.1 除非提名委員會全體成員另有協定，否則召開提名委員會會議的通知須於會 議召開前不少於兩個工作天發出。 1 1.1 本公司提名委員會（「提名委員會」）由本公司董事會（「董事會」）設立，且須由 不少於三名成員組成，而至少一名成員為不同性別。 1.2 大部分提名委員會成員應為獨立非執行董事，並符合《香港聯合交易所有限 公司證券上市規則》（「上市規則」）（經不時修訂）所規定的獨立性要求。提名 委員會主席須為董事會主席或提名委員會內的獨立非執行董事。提名委員會 成員及主席應由董事會委任及罷免。 1.3 提名委員會成員不得自行委任任何候補人出席會議或履行其職務。 1.4 提名委員會成員的委任年期須由董事會於委任之日決定。 1.5 提名委員會的會議及程序須受本公司組織章程細則中有關董事會會議程序的 規定所規管。 2.1 ...

Group 1 - Hong Kong stocks opened slightly higher on September 23, with the Hong Kong Stock Connect Technology ETF (513860) rising by 0.23% at the time of reporting [1] - Notable gainers among the ETF's constituent stocks included InnoCare Pharma and Crystal International, both up over 3%, along with other companies like BYD Electronics and Kingsoft [1] - The Hong Kong Stock Connect Technology ETF closely tracks the CSI Hong Kong Stock Connect Technology Index, which selects 50 large-cap, high R&D investment, and fast-growing revenue technology companies to reflect the overall performance of technology leaders in the Hong Kong Stock Connect [1] Group 2 - According to Huatai Securities, the release of DeepSeek at the beginning of the year triggered the first round of revaluation of Chinese technology assets, with a second upward trend in tech stocks occurring in the third quarter due to AI concepts [2] - The recent rapid rebound in Hong Kong technology stocks is attributed to accelerated domestic AI developments, and there is potential for further improvement in market sentiment [2] - The current focus of technology companies on growth, combined with a stable domestic economic and policy environment, has reduced the equity risk premium [2]

Core Viewpoint - InnoSpace (02577) has seen a significant stock increase following its collaboration with a leading robotics company to launch the world's first gallium nitride (GaN) robot, indicating strong market potential and technological advancement [1] Company Performance - InnoSpace reported a sales revenue of 553 million yuan for the first half of the year, representing a year-on-year growth of 43.4% [1] - The company achieved a gross margin of 6.8%, marking a substantial improvement of 28.4 percentage points compared to the same period in 2024, and this is the first time the company recorded a positive gross margin [1] - The net loss narrowed to approximately 429 million yuan, a decrease of 12.16% year-on-year [1] Product Development - The company anticipates that the shipment of GaN chips for robots will exceed 10,000 units this year, with each robot requiring about 300 GaN chips [1] - As technology continues to evolve, the demand for GaN chips in humanoid robots is expected to rise significantly, with the usage per robot projected to increase to 1,000 chips to enable more complex movements in key areas such as fingers and waist [1] Market Trends - Sales targeting AI and data centers surged by 180% year-on-year, indicating a strong demand in these sectors [1] - The company has entered mass production for its 100V GaN applications in 48V-12V systems, showcasing its commitment to innovation and market readiness [1]

Core Viewpoint - InnoCare (02577) has partnered with a leading robotics company to launch the world's first gallium nitride (GaN) robot, which is expected to significantly increase the demand for GaN chips in humanoid robots [1] Group 1: Company Performance - InnoCare's stock rose over 5% in early trading, reaching 100.5 HKD with a trading volume of 175 million HKD [1] - The company reported a sales revenue of 553 million CNY for the first half of the year, representing a year-on-year growth of 43.4% [1] - The gross margin improved to 6.8%, a significant increase of 28.4 percentage points compared to the same period in 2024, marking the first time the company recorded a positive gross margin [1] - The net loss narrowed to approximately 429 million CNY, a decrease of 12.16% year-on-year [1] Group 2: Product Development and Market Demand - The company anticipates that the shipment of GaN chips for robots will exceed 10,000 units this year, with each robot requiring about 300 GaN chips [1] - As technology continues to evolve, the demand for GaN chips in humanoid robots is expected to rise significantly, with the usage per robot projected to increase to 1,000 chips to enable more complex movements in key areas such as fingers and waist [1] - Sales targeting AI and data centers grew by 180% year-on-year, with the 100V GaN-based 48V-12V applications entering mass production [1]

Core Insights - The article highlights the changes in the Hong Kong Stock Connect holdings, with notable increases and decreases in ownership percentages for various companies [1][2]. Group 1: Increased Holdings - Heng Rui Medicine (01276) saw the largest increase in ownership percentage, rising by 1.49% to a total of 13.84% [2]. - Kanglong Chemical (03759) experienced a 1.35% increase, bringing its ownership to 60.51% [2]. - Zhaoyan New Drug (06127) increased by 1.27%, reaching a holding of 43.70% [2]. - Other companies with significant increases include Junshi Biosciences (01877) at +1.24% (59.08%) and China Pacific Insurance (02601) at +1.20% (44.16%) [2]. Group 2: Decreased Holdings - Shandong Molong (00568) had the largest decrease, with a drop of 1.99% to 57.67% [2]. - Yisou Technology (02550) decreased by 0.99%, now holding 37.95% [2]. - Nanjing Panda Electronics (00553) saw a reduction of 0.98%, bringing its ownership to 42.65% [2]. - Other notable decreases include Kailai Ying (06821) at -0.95% (43.35%) and Meizhong Jiahe (02453) at -0.95% (32.06%) [2]. Group 3: Five-Day Changes - In the last five trading days, China Merchants Energy (01138) had the highest increase in ownership, up by 6.19% to 65.63% [3]. - Shandong Molong (00568) also saw a significant increase of 3.74% [3]. - Other companies with notable increases include Zhongchu Innovation (03931) at +3.62% (10.35%) and Youbao Online (02429) at +3.33% (17.38%) [3]. Group 4: Twenty-Day Changes - Over the past twenty days, Anjiren Food (02648) experienced the largest increase, up by 12.29% to 20.54% [4]. - China Merchants Energy (01138) also saw a significant increase of 9.07% [4]. - Other companies with notable increases include Yimai Sunshine (02522) at +7.70% (43.02%) and Lens Technology (06613) at +7.56% (13.64%) [4].